NCT06870942View on ClinicalTrials.gov

Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2025

Conditions
HCC - Hepatocellular CarcinomaRadiotherapy
Interventions
DRUG

Maintenance first-line treatment plus radiation therapy

Maintenance first-line treatment plus radiation therapy

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER